Halozyme Therapeutics（NASDAQ:HALO）公布了季度财报，公司调整后每股收益为$1.26，高于分析师普遍预期的$1.16，上涨幅度达8.62%。与去年同期的每股收益$0.82相比，这一数字增长了53.66%。公司报告的本季度销售额为$2.98亿，超出分析师预期的$2.88亿，超出幅度为3.39%。较去年同期$2.30亿的销售额相比增加了29.54%。

以上内容来自Benzinga Earnings专栏，原文如下：

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.16 by 8.62 percent. This is a 53.66 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $298.00 million which beat the analyst consensus estimate of $288.24 million by 3.39 percent. This is a 29.54 percent increase over sales of $230.04 million the same period last year.